BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79:667-668. [PMID: 32241793 DOI: 10.1136/annrheumdis-2020-217424] [Cited by in Crossref: 282] [Cited by in F6Publishing: 254] [Article Influence: 141.0] [Reference Citation Analysis]
Number Citing Articles
1 Pelechas E, Drossou V, Voulgari PV, Drosos AA. COVID-19 in patients with gout on colchicine. Rheumatol Int 2021;41:1503-7. [PMID: 34089357 DOI: 10.1007/s00296-021-04902-7] [Reference Citation Analysis]
2 Lauper K, Bijlsma JWJ, Burmester GR. Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic. Ann Rheum Dis 2021;80:26-30. [PMID: 33055081 DOI: 10.1136/annrheumdis-2020-219217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Tan EH, Sena AG, Prats-Uribe A, You SC, Ahmed WU, Kostka K, Reich C, Duvall SL, Lynch KE, Matheny ME, Duarte-Salles T, Bertolin SF, Hripcsak G, Natarajan K, Falconer T, Spotnitz M, Ostropolets A, Blacketer C, Alshammari TM, Alghoul H, Alser O, Lane JCE, Dawoud DM, Shah K, Yang Y, Zhang L, Areia C, Golozar A, Recalde M, Casajust P, Jonnagaddala J, Subbian V, Vizcaya D, Lai LYH, Nyberg F, Morales DR, Posada JD, Shah NH, Gong M, Vivekanantham A, Abend A, Minty EP, Suchard M, Rijnbeek P, Ryan PB, Prieto-Alhambra D. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford) 2021;60:SI37-50. [PMID: 33725121 DOI: 10.1093/rheumatology/keab250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
4 El Dannan H, Al Hassani M, Ramsi M. Clinical course of COVID-19 among immunocompromised children: a clinical case series. BMJ Case Rep 2020;13:e237804. [PMID: 33130585 DOI: 10.1136/bcr-2020-237804] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
5 Nuño L, Novella Navarro M, Bonilla G, Franco-Gómez K, Aguado P, Peiteado D, Monjo I, Tornero C, Villalba A, Miranda-Carus ME, De Miguel E, Bogas P, Castilla-Plaza A, Bernad-Pineda M, García-Lorenzo E, Rodríguez-Araya T, Balsa A. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis 2020;79:1659-61. [PMID: 32606046 DOI: 10.1136/annrheumdis-2020-218054] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
6 Stradner MH, Dejaco C, Zwerina J, Fritsch-Stork RD. Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. Front Med (Lausanne) 2020;7:562142. [PMID: 33154972 DOI: 10.3389/fmed.2020.562142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Tam LS, Tanaka Y, Handa R, Li Z, Lorenzo JP, Louthrenoo W, Hill C, Pile K, Robinson PC, Dans LF, Hsu LY, Lee SM, Cho J, Hasan ATMT, Salim B, Samreen S, Shaharir SS, Wong P, Chau J, Danda D, Haq SA. Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. Int J Rheum Dis 2021;24:733-45. [PMID: 33945214 DOI: 10.1111/1756-185X.14124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Monti S, Montecucco C. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak. Ann Rheum Dis 2020:annrheumdis-2020-217957. [PMID: 32503855 DOI: 10.1136/annrheumdis-2020-217957] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Colafrancesco S, Scrivo R, Barbati C, Conti F, Priori R. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients. Front Immunol 2020;11:1439. [PMID: 32655577 DOI: 10.3389/fimmu.2020.01439] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
10 Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol 2020;16:465-70. [PMID: 32561873 DOI: 10.1038/s41584-020-0451-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 28.0] [Reference Citation Analysis]
11 Ziadé N, El Kibbi L, Hmamouchi I, Abdulateef N, Halabi H, Hamdi W, Abutiban F, El Rakawi M, Eissa M, Masri B. Impact of the COVID-19 pandemic on patients with chronic rheumatic diseases: A study in 15 Arab countries. Int J Rheum Dis 2020;23:1550-7. [PMID: 32892516 DOI: 10.1111/1756-185X.13960] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
12 Fitzgerald GE, Maguire S, Haroon N. COVID-19: What Do Rheumatologists Need to Know? Curr Rheumatol Rep. 2021;23:5. [PMID: 33403528 DOI: 10.1007/s11926-020-00971-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, Colomer JI, Jover JA, Fernandez-Gutierrez B, Abasolo L. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79:1393-9. [PMID: 32769150 DOI: 10.1136/annrheumdis-2020-217984] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
14 Kokkotis G, Kitsou K, Xynogalas I, Spoulou V, Magiorkinis G, Trontzas I, Trontzas P, Poulakou G, Syrigos K, Bamias G. Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments. Aliment Pharmacol Ther 2022;55:154-67. [PMID: 34881430 DOI: 10.1111/apt.16717] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
15 Drosos AA, Pelechas E, Drossou V, Voulgari PV. Colchicine Against SARS-CoV-2 Infection: What is the Evidence? Rheumatol Ther 2022. [PMID: 35107804 DOI: 10.1007/s40744-022-00425-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Faraone I, Labanca F, Ponticelli M, De Tommasi N, Milella L. Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. Molecules 2020;25:E5318. [PMID: 33202656 DOI: 10.3390/molecules25225318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Haslak F, Varol SE, Gunalp A, Kaynar O, Yildiz M, Adrovic A, Sahin S, Kes G, Ayzit-kilinc A, Akdeniz B, Onal P, Apaydin G, Aygun D, Arslan H, Kilic-baskan A, Hepkaya E, Meral O, Barut K, Cokugras HC, Kasapcopur O. Comparisons of Clinical Features and Outcomes of COVID-19 between Patients with Pediatric Onset Inflammatory Rheumatic Diseases and Healthy Children. JCM 2022;11:2102. [DOI: 10.3390/jcm11082102] [Reference Citation Analysis]
18 Favalli EG, Bugatti S, Klersy C, Biggioggero M, Rossi S, De Lucia O, Bobbio-Pallavicini F, Murgo A, Balduzzi S, Caporali R, Montecucco C. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther 2020;22:290. [PMID: 33380344 DOI: 10.1186/s13075-020-02395-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
19 Ali T, Al-Ali A, Fajji L, Hammad E, Nazmi A, Alahmadi I, Aleid H, Ullah A, Shah Y, Broering D. Coronavirus Disease-19: Disease Severity and Outcomes of Solid Organ Transplant Recipients: Different Spectrums of Disease in Different Populations? Transplantation 2021;105:121-7. [PMID: 32852405 DOI: 10.1097/TP.0000000000003433] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
20 Soldevila-Domenech N, Tío L, Llorente-Onaindia J, Martín-García E, Nebot P, de la Torre R, Gurt A, Maldonado R, Monfort J; Covidmar Study Group. COVID-19 Incidence in Patients With Immunomediated Inflammatory Diseases: Influence of Immunosuppressant Treatments. Front Pharmacol 2020;11:583260. [PMID: 33519443 DOI: 10.3389/fphar.2020.583260] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Morales-Torres J, Aceves-Ávila FJ. Rheumatologists in the COVID-19 era: will there be a new role for the rheumatologist in the care of rheumatic patients? Clin Rheumatol 2020;39:3177-83. [PMID: 32889590 DOI: 10.1007/s10067-020-05380-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Massalska M, Maslinski W, Ciechomska M. Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. Cells 2020;9:E1876. [PMID: 32796683 DOI: 10.3390/cells9081876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
23 Schulze-Koops H, Iking-Konert C, Leipe J, Hoyer BF, Holle J, Moosig F, Aries P, Burmester G, Fiehn C, Krause A, Lorenz HM, Schneider M, Sewerin P, Voormann A, Wagner U, Krüger K, Specker C; Kommission Pharmakotherapie., Vorstand der Deutschen Gesellschaft für Rheumatologie. [Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020]. Z Rheumatol 2020;79:679-85. [PMID: 32757030 DOI: 10.1007/s00393-020-00851-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
24 Ladani AP, Loganathan M, Danve A. Managing rheumatic diseases during COVID-19. Clin Rheumatol 2020;39:3245-54. [PMID: 32895747 DOI: 10.1007/s10067-020-05387-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
25 Cleaton N, Raizada S, Barkham N, Venkatachalam S, Sheeran TP, Adizie T, Sapkota H, Singh BM, Bateman J. The impact of COVID-19 on rheumatology patients in a large UK centre using an innovative data collection technique: prevalence and effect of social shielding. Rheumatol Int 2021;41:707-14. [PMID: 33559727 DOI: 10.1007/s00296-021-04797-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
26 Veenstra J, Buechler CR, Robinson G, Chapman S, Adelman M, Tisack A, Dimitrion P, Todter E, Kohen L, Lim HW. Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak. J Am Acad Dermatol 2020;83:1696-703. [PMID: 32735965 DOI: 10.1016/j.jaad.2020.07.089] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
27 Marcus N, Frizinsky S, Hagin D, Ovadia A, Hanna S, Farkash M, Maoz-Segal R, Agmon-Levin N, Broides A, Nahum A, Rosenberg E, Kuperman AA, Dinur-Schejter Y, Berkun Y, Toker O, Goldberg S, Confino-Cohen R, Scheuerman O, Badarneh B, Epstein-Rigbi N, Etzioni A, Dalal I, Somech R. Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel. Front Immunol 2020;11:614086. [PMID: 33519822 DOI: 10.3389/fimmu.2020.614086] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
28 Haşlak F, Yıldız M, Adrovic A, Barut K, Kasapçopur Ö. Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon. Balkan Med J 2020;37:184-8. [PMID: 32264666 DOI: 10.4274/balkanmedj.galenos.2020.2020.4.43] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
29 Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 2020;79:1382-3. [PMID: 32398281 DOI: 10.1136/annrheumdis-2020-217717] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 25.5] [Reference Citation Analysis]
30 Mcinnes IB. COVID-19 and rheumatology: first steps towards a different future? Ann Rheum Dis 2020;79:551-2. [DOI: 10.1136/annrheumdis-2020-217494] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 20.5] [Reference Citation Analysis]
31 Banerjee S, George M, Young K, Venkatachalam S, Gordon J, Burroughs C, Curtis D, Ferrada M, Gavigan K, Grayson PC, Kullman J, Danila MI, Curtis JR, Shaw DG, Benjamin Nowell W, Merkel PA; Vasculitis Patient‐Powered Research Network. Effects of the COVID-19 Pandemic on Patients Living With Vasculitis. ACR Open Rheumatol 2021;3:17-24. [PMID: 33784021 DOI: 10.1002/acr2.11204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Filocamo G, Minoia F, Carbogno S, Costi S, Romano M, Cimaz R. Absence of Severe Complications From SARS-CoV-2 Infection in Children With Rheumatic Diseases Treated With Biologic Drugs. J Rheumatol 2021;48:1343.1-1344. [DOI: 10.3899/jrheum.200483] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 15.0] [Reference Citation Analysis]
33 Baek MS, Lee MT, Kim WY, Choi JC, Jung SY. COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea. PLoS One 2021;16:e0257641. [PMID: 34597325 DOI: 10.1371/journal.pone.0257641] [Reference Citation Analysis]
34 Giollo A, Cioffi G, Rossini M, Viapiana O, De Simone G. Very low reporting rate of connective tissue diseases among coronavirus disease 2019 (Covid-19) patients and the renin-angiotensin system - An overlooked association? Eur J Intern Med 2020;80:106-7. [PMID: 32553588 DOI: 10.1016/j.ejim.2020.06.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Bakasis AD, Mavragani CP, Boki KA, Tzioufas AG, Vlachoyiannopoulos PG, Stergiou IE, Skopouli FN, Moutsopoulos HM. COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. J Autoimmun 2021;123:102687. [PMID: 34311142 DOI: 10.1016/j.jaut.2021.102687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Leipe J, Hoyer BF, Iking-Konert C, Schulze-Koops H, Specker C, Krüger K. [SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments]. Z Rheumatol 2020;79:686-91. [PMID: 32845393 DOI: 10.1007/s00393-020-00878-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
37 Moura CA, Moura CG, Cerqueira De Sant’ana Costa AL. SARS-CoV-2: Viral Mechanisms and Possible Therapeutic Targets — What to Learn from Rheumatologists. J Rheumatol 2020;47:1588-9. [DOI: 10.3899/jrheum.200657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wahezi DM, Lo MS, Rubinstein TB, Ringold S, Ardoin SP, Downes KJ, Jones KB, Laxer RM, Pellet Madan R, Mudano AS, Turner AS, Karp DR, Mehta JJ. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol 2021;73:e46-59. [PMID: 34114365 DOI: 10.1002/art.41772] [Reference Citation Analysis]
39 Serling-Boyd N, D'Silva KM, Hsu TY, Wallwork R, Fu X, Gravallese EM, Jorge AM, Zhang Y, Choi H, Sparks JA, Wallace ZS. Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis 2021;80:660-6. [PMID: 33257496 DOI: 10.1136/annrheumdis-2020-219279] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
40 Fernandez-Gutierrez B, Leon L, Madrid A, Rodriguez-Rodriguez L, Freites D, Font J, Mucientes A, Culebras E, Colome JI, Jover JA, Abasolo L. Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents. Ther Adv Musculoskelet Dis 2021;13:1759720X20962692. [PMID: 33613703 DOI: 10.1177/1759720X20962692] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
41 Conway R, Konig MF, Graef ER, Webb K, Yazdany J, Kim AHJ. Inflammatory arthritis in patients with COVID-19. Transl Res 2021;232:49-59. [PMID: 33626415 DOI: 10.1016/j.trsl.2021.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F; Brescia Rheumatology COVID-19 Study Group. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol 2020;2:e549-56. [PMID: 32838307 DOI: 10.1016/S2665-9913(20)30169-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 28.0] [Reference Citation Analysis]
43 Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin Infect Dis. 2021;72:340-350. [PMID: 33501974 DOI: 10.1093/cid/ciaa863] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 95.0] [Reference Citation Analysis]
44 Tan EH, Sena AG, Prats-Uribe A, You SC, Ahmed WU, Kostka K, Reich C, Duvall SL, Lynch KE, Matheny ME, Duarte-Salles T, Bertolin SF, Hripcsak G, Natarajan K, Falconer T, Spotnitz M, Ostropolets A, Blacketer C, Alshammari TM, Alghoul H, Alser O, Lane JCE, Dawoud DM, Shah K, Yang Y, Zhang L, Areia C, Golozar A, Relcade M, Casajust P, Jonnagaddala J, Subbian V, Vizcaya D, Lai LY, Nyberg F, Morales DR, Posada JD, Shah NH, Gong M, Vivekanantham A, Abend A, Minty EP, Suchard M, Rijnbeek P, Ryan PB, Prieto-Alhambra D. Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19: a multinational distributed network cohort analysis. medRxiv 2020:2020. [PMID: 33269355 DOI: 10.1101/2020.11.24.20236802] [Reference Citation Analysis]
45 Felten R, Chatelus E, Arnaud L. How and why are rheumatologists relevant to COVID-19? Joint Bone Spine 2020;87:279-80. [PMID: 32451147 DOI: 10.1016/j.jbspin.2020.04.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
46 Galloway J, Bukhari M. COVID-19 and mortality in rare rheumatic diseases, a warning bell? Rheumatology (Oxford) 2021;60:1580-1. [PMID: 33410464 DOI: 10.1093/rheumatology/keaa889] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Moiseev S, Avdeev S, Brovko M, Yavorovskiy A, Novikov PI, Umbetova K, Akulkina L, Tsareva N, Fomin V. Rheumatic diseases in intensive care unit patients with COVID-19. Ann Rheum Dis 2021;80:e16. [PMID: 32434823 DOI: 10.1136/annrheumdis-2020-217676] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
48 Grinshpun A, Merlet I, Fruchtman H, Nachman D. A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy. Front Oncol 2020;10:1085. [PMID: 32582559 DOI: 10.3389/fonc.2020.01085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
49 Bazmjoo A, Bagherzadeh MA, Farahmandpoor F, Raoofi R, Abdoli A. SARS-CoV-2 infection in an advanced rheumatoid arthritis patient. APMIS 2020;128:654-6. [PMID: 32945021 DOI: 10.1111/apm.13080] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Mena-Vázquez N, Manrique Arija S, Rojas-Giménez M, Raya-Álvarez E, Velloso-Feijoó ML, López-Medina C, Ramos-Giraldez C, Godoy-Navarrete FJ, Redondo-Rodríguez R, Cabezas-Lucena AM, Morales-Águila M, Romero-Barco CM, Fernández-Nebro A. Hospitalization and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia. Reumatol Clin (Engl Ed) 2021:S2173-5743(21)00162-3. [PMID: 34538612 DOI: 10.1016/j.reumae.2021.02.006] [Reference Citation Analysis]
51 Beketova TV, Blank LM, Lila AM. Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab). Naučno-praktičeskaâ revmatologiâ 2020;58:456-62. [DOI: 10.47360/1995-4484-2020-456-462] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
52 Findeisen KE, Sewell J, Ostor AJK. Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician. Biologics 2021;15:343-52. [PMID: 34413630 DOI: 10.2147/BTT.S252575] [Reference Citation Analysis]
53 Schulze-koops H, Krueger K, Specker C. Response to: ‘Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic’ by Fragoulis et al. Ann Rheum Dis 2021;80:e61-e61. [DOI: 10.1136/annrheumdis-2020-217987] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
54 Price E, MacPhie E, Kay L, Lanyon P, Griffiths B, Holroyd C, Abhishek A, Youngstein T, Bailey K, Clinch J, Shaikh M, Rivett A. Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. Clin Med (Lond) 2020:clinmed. [PMID: 32371418 DOI: 10.7861/clinmed.2020-0149] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 10.5] [Reference Citation Analysis]
55 Wahezi DM, Lo MS, Rubinstein TB, Ringold S, Ardoin SP, Downes KJ, Jones KB, Laxer RM, Pellet Madan R, Mudano AS, Turner AS, Karp DR, Mehta JJ. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol 2020;72:1809-19. [PMID: 32705780 DOI: 10.1002/art.41455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
56 Hu H, He C. Identification of Diagnostic Gene Markers and Immune Infiltration in Systemic Lupus. Comput Math Methods Med 2022;2022:3386999. [PMID: 35558576 DOI: 10.1155/2022/3386999] [Reference Citation Analysis]
57 Gupta Y, Kishore A, Kumari P, Balakrishnan N, Lomi N, Gupta N, Vanathi M, Tandon R. Peripheral ulcerative keratitis. Surv Ophthalmol 2021;66:977-98. [PMID: 33657431 DOI: 10.1016/j.survophthal.2021.02.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Monti S, Montecucco C. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al. Ann Rheum Dis 2021;80:e3. [PMID: 32340978 DOI: 10.1136/annrheumdis-2020-217545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
59 Spini A, Giudice V, Brancaleone V, Morgese MG, De Francia S, Filippelli A, Ruggieri A, Ziche M, Ortona E, Cignarella A, Trabace L. Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacol Res 2021;173:105848. [PMID: 34454035 DOI: 10.1016/j.phrs.2021.105848] [Reference Citation Analysis]
60 Moutsopoulos HM. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19. Ann Rheum Dis. 2020;79:1253-1254. [PMID: 32345616 DOI: 10.1136/annrheumdis-2020-217562] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
61 Kobak S. COVID-19 infection in a patient with FMF: does colchicine have a protective effect? Ann Rheum Dis 2020:annrheumdis-2020-217882. [PMID: 32503853 DOI: 10.1136/annrheumdis-2020-217882] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
62 Wen J, Suo H, Zhang Y, Tao J. Risk of COVID-19 infection among lupus erythematosus patients and rheumatoid arthritis patients: a retrospective study in Hubei, China. Eur J Dermatol 2020;30:751-3. [PMID: 33289491 DOI: 10.1684/ejd.2020.3926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
63 Talotta R, Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J Clin Cases 2020; 8(17): 3621-3644 [PMID: 32953841 DOI: 10.12998/wjcc.v8.i17.3621] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 25] [Article Influence: 18.5] [Reference Citation Analysis]
64 Campanati A, Brisigotti V, Diotallevi F, D'Agostino GM, Paolinelli M, Radi G, Rizzetto G, Sapigni C, Tagliati C, Offidani A. Active implications for dermatologists in 'SARS-CoV-2 ERA': Personal experience and review of literature. J Eur Acad Dermatol Venereol 2020;34:1626-32. [PMID: 32426855 DOI: 10.1111/jdv.16646] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
65 Junginger A, Brucke M, Reiser B, Stahn O, Braun G. [Hemoptysis and acute kidney injury in COVID-19]. Med Klin Intensivmed Notfmed 2020;115:146-51. [PMID: 33315119 DOI: 10.1007/s00063-020-00762-4] [Reference Citation Analysis]
66 Martínez-Taboada VM, López-Hoyos M, Crespo J, Hernández JL. COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse? Autoimmun Rev 2020;19:102683. [PMID: 33127600 DOI: 10.1016/j.autrev.2020.102683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Roongta R, Ghosh A. Managing rheumatoid arthritis during COVID-19. Clin Rheumatol 2020;39:3237-44. [PMID: 32892311 DOI: 10.1007/s10067-020-05358-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
68 Blagova O, Varionchik N, Zaidenov V, Savina P, Sarkisova N. Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19. Eur J Immunol 2021;51:893-902. [PMID: 33368288 DOI: 10.1002/eji.202048930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
69 Gamboa-Cárdenas RV, Barzola-Cerrón S, Toledo-Neira D, Reátegui-Sokolova C, Pimentel-Quiroz V, Zevallos-Miranda F, Alarcón GS, Ugarte-Gil M. Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. Clin Rheumatol 2021. [PMID: 34189675 DOI: 10.1007/s10067-021-05833-1] [Reference Citation Analysis]
70 Vertui V, Zanframundo G, Castañeda S, Biglia A, Palermo BL, Cavazzana I, Meloni F, Cavagna L. Clinical evolution of antisynthetase syndrome after SARS-CoV2 infection: a 6-month follow-up analysis. Clin Rheumatol 2022. [PMID: 35612768 DOI: 10.1007/s10067-022-06216-w] [Reference Citation Analysis]
71 Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, Wu B, Zhang A, Su L, Hou X, Song S, Li H, Zhou W, Zhou T, Huang Q, Chu A, Braunstein Z, Rao X, Ye C, Dong L. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2020;2:e557-64. [PMID: 32838309 DOI: 10.1016/S2665-9913(20)30227-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 18.5] [Reference Citation Analysis]
72 Romão VC, Cruz-Machado AR, Fonseca JE. Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli et al. Ann Rheum Dis 2021;80:e76. [PMID: 32561609 DOI: 10.1136/annrheumdis-2020-218175] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Blicharz L, Czuwara J, Samochocki Z, Goldust M, Olszewska M, Rudnicka L. Immunosuppressive treatment for systemic sclerosis-Therapeutic challenges during the COVID-19 pandemic. Dermatol Ther 2020;33:e13619. [PMID: 32428315 DOI: 10.1111/dth.13619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Mena-Vázquez N, Manrique Arija S, Rojas-Giménez M, Raya-Álvarez E, Velloso-Feijoó ML, López-Medina C, Ramos-Giraldez C, Godoy-Navarrete FJ, Redondo-Rodríguez R, Cabezas-Lucena AM, Morales-Águila M, Romero-Barco CM, Fernández-Nebro A. Hospitalization and Mortality from COVID-19 of Patients with Rheumatic Inflammatory Diseases in Andalusia. Reumatol Clin (Engl Ed) 2021:S1699-258X(21)00089-9. [PMID: 33895100 DOI: 10.1016/j.reuma.2021.02.009] [Reference Citation Analysis]
75 Zateri C, Birtane M, Aktaş İ, Sarıkaya S, Rezvani A, Altan L, Dursun N, Dursun E, Taştekin N, Çeliker R, Özdolap Ş, Akgün K. Attitudes of patients with spondylarthritis or rheumatoid arthritis regarding biological treatment during COVID-19 pandemic: A multi-center, phone-based, cross-sectional study. Arch Rheumatol 2021;36:473-81. [DOI: 10.46497/archrheumatol.2021.8364] [Reference Citation Analysis]
76 Murtas R, Andreano A, Gervasi F, Guido D, Consolazio D, Tunesi S, Andreoni L, Greco MT, Gattoni ME, Sandrini M, Riussi A, Russo AG. Association between autoimmune diseases and COVID-19 as assessed in both a test-negative case-control and population case-control design. Auto Immun Highlights 2020;11:15. [PMID: 33023649 DOI: 10.1186/s13317-020-00141-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
77 Daniel P, Raad M, Waked R, Choucair J, Riachy M, Haddad F. COVID-19 in a Patient Treated for Granulomatosis with Polyangiitis: Persistent Viral Shedding with No Cytokine Storm. Eur J Case Rep Intern Med 2020;7:001922. [PMID: 33083371 DOI: 10.12890/2020_001922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
78 Nuñez DF, Leon L, Garcia AM, Arce JIC, Mucientes A, Gutierrez-fernandez B, Rodriguez L, Cristóbal IPS, Álvarez P, Prada CM, Abasolo L. Mortality related to COVID-19 in patients with rheumatic and musculoskeletal diseases, first wave of the outbreak: a single-center study. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210902. [DOI: 10.1177/1759720x221090296] [Reference Citation Analysis]
79 Benoy S, Traksel R, Verhaegh P, Broen J. COVID-19 in rheumatology outpatient clinics: Dutch mirror image to Lombardy, Italy. Ann Rheum Dis 2020:annrheumdis-2020-217765. [PMID: 32493726 DOI: 10.1136/annrheumdis-2020-217765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. J Clin Med 2021;10:509. [PMID: 33535498 DOI: 10.3390/jcm10030509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Koutsianas C, Chatzidionysiou K. The Rheumatologist's Role in the Battle Against COVID-19: Insights from the Front Line and Challenges for the Future. Mediterr J Rheumatol 2020;31:247-52. [PMID: 33196000 DOI: 10.31138/mjr.31.3.247] [Reference Citation Analysis]
82 Ridruejo E, Soza A. The liver in times of COVID-19: What hepatologists should know. Ann Hepatol. 2020;19:353-358. [PMID: 32425991 DOI: 10.1016/j.aohep.2020.05.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
83 Bellan M, Parisi S, Stobbione P, Pedrinelli AR, Rizzi E, Casciaro GF, Vassia V, Landi R, Cittone MG, Rigamonti C, Patrucco F, Ditto MC, Finucci A, Realmuto C, Todoerti M, Parodi M, Rossi P, Pirisi M, Fusaro E, Sainaghi PP. Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients. Scand J Rheumatol 2020;49:505-6. [PMID: 32856492 DOI: 10.1080/03009742.2020.1800083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
84 Dewanjee S, Kandimalla R, Kalra RS, Valupadas C, Vallamkondu J, Kolli V, Dey Ray S, Reddy AP, Reddy PH. COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges. Cells 2021;10:3291. [PMID: 34943795 DOI: 10.3390/cells10123291] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Keskin Y, Koz G, Nas K. What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19? Eurasian J Med 2021;53:132-6. [PMID: 34177297 DOI: 10.5152/eurasianjmed.2021.20222] [Reference Citation Analysis]
86 Cacciapaglia F, Manfredi A, Erre G, Piga M, Sakellariou G, Viapiana O, Gremese E, Spinelli FR, Atzeni F, Bartoloni E. Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients. Ann Rheum Dis 2020:annrheumdis-2020-218813. [PMID: 32933920 DOI: 10.1136/annrheumdis-2020-218813] [Reference Citation Analysis]
87 Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, Santos GPJ, Reis-Neto ET, Matos P, Devide G, Dantas A, Giorgi RD, Marinho AO, Valadares LDA, Melo AKG, Ribeiro FM, Ferreira GA, Santos FPS, Ribeiro SLE, Andrade NPB, Yazbek MA, Souza VA, Paiva ES, Azevedo VF, Freitas ABSB, Provenza JR, Toledo RA, Fontenelle S, Carneiro S, Xavier R, Pileggi GCS, Reis APMG. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open 2021;7:e001461. [PMID: 33510041 DOI: 10.1136/rmdopen-2020-001461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
88 Colafrancesco S, Alessandri C, Conti F, Priori R. COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? Autoimmun Rev. 2020;19:102573. [PMID: 32387470 DOI: 10.1016/j.autrev.2020.102573] [Cited by in Crossref: 96] [Cited by in F6Publishing: 78] [Article Influence: 48.0] [Reference Citation Analysis]
89 Arslanoglu Aydin E, Baglan E, Bagrul I, Tuncez S, Ozdel S, Bulbul M. Safety of COVID-19 vaccines and disease flares after vaccines in children with rheumatic disease. Postgrad Med 2022. [PMID: 35535525 DOI: 10.1080/00325481.2022.2074700] [Reference Citation Analysis]
90 Praliaud R, Greigert H, Samson M, Zeller M, Boulin M, Bielefeld P, Ramon A, Cottin Y, Bonnotte B. Impact of the COVID-19 lockdown on the management and control of patients with GCA. Ann Rheum Dis 2021;80:e102-e102. [DOI: 10.1136/annrheumdis-2020-218360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
91 Plaçais L, Richier Q. [COVID-19: Clinical, biological and radiological characteristics in adults, infants and pregnant women. An up-to-date review at the heart of the pandemic]. Rev Med Interne 2020;41:308-18. [PMID: 32334862 DOI: 10.1016/j.revmed.2020.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
92 Esmaeilzadeh A, Elahi R. Immunobiology and immunotherapy of COVID-19: A clinically updated overview. J Cell Physiol 2021;236:2519-43. [PMID: 33022076 DOI: 10.1002/jcp.30076] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
93 Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, Colomer JI, Jover JA, Fernandez-Gutierrez B, Abasolo L. Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Aydin et al. Ann Rheum Dis 2020:annrheumdis-2020-219580. [PMID: 33355105 DOI: 10.1136/annrheumdis-2020-219580] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
94 Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus EF, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham KD, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Wallace ZS, Yazdany J, Machado PM, Robinson PC;  COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859-866. [PMID: 32471903 DOI: 10.1136/annrheumdis-2020-217871] [Cited by in Crossref: 402] [Cited by in F6Publishing: 376] [Article Influence: 201.0] [Reference Citation Analysis]
95 Gartshteyn Y, Askanase AD, Schmidt NM, Bernstein EJ, Khalili L, Drolet R, Broderick RJ, Geraldino-Pardilla L, Kapoor T. COVID-19 and systemic lupus erythematosus: a case series. Lancet Rheumatol 2020;2:e452-4. [PMID: 32835249 DOI: 10.1016/S2665-9913(20)30161-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
96 Francesconi P, Cantini F, Profili F, Mannoni A, Bellini B, Benucci M. COVID-19 epidemiology in rheumatic diseases in Tuscany: A case-control study. Joint Bone Spine 2021;88:105131. [PMID: 33486110 DOI: 10.1016/j.jbspin.2021.105131] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
97 Fatone MC. COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations? Curr Rheumatol Rev 2021;17:7-16. [PMID: 33019935 DOI: 10.2174/1573397116666201005122603] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Cajamarca-Baron J, Guavita-Navarro D, Buitrago-Bohorquez J, Gallego-Cardona L, Navas A, Cubides H, Arredondo AM, Escobar A, Rojas-Villarraga A. SARS-CoV-2 (COVID-19) in patients with some degree of immunosuppression. Reumatol Clin (Engl Ed) 2021;17:408-19. [PMID: 34301385 DOI: 10.1016/j.reumae.2020.08.001] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Palmeira P, Barbuto JAM, Silva CAA, Carneiro-sampaio M. Why is SARS-CoV-2 infection milder among children? Clinics 2020;75:e1947. [DOI: 10.6061/clinics/2020/e1947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
100 Siegel CH, Choi JM, D'Angelo D, Christos P, Lally L, Navarro-Millan I, Cooke J, Goyal P, Mandl LA, Barbhaiya M. Outcomes of COVID-19 and Factors Associated With Its Severity Among Hospitalized Patients With and Without Systemic Rheumatic Disease During the First Wave of the Pandemic in New York City. J Clin Rheumatol 2022. [PMID: 35905465 DOI: 10.1097/RHU.0000000000001891] [Reference Citation Analysis]
101 Migkos MP, Kaltsonoudis E, Pelechas E, Drossou V, Karagianni PG, Kavvadias A, Voulgari PV, Drosos AA. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatol Int 2021;41:903-9. [PMID: 33655421 DOI: 10.1007/s00296-021-04818-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Chung TW, Sridhar S, Zhang AJ, Chan KH, Li HL, Wong FK, Ng MY, Tsang RK, Lee AC, Fan Z, Ho RS, Luk SY, Kan WK, Lam SH, Wu AK, Leung SM, Chan WM, Ng PY, To KK, Cheng VC, Lung KC, Hung IF, Yuen KY. Olfactory Dysfunction in Coronavirus Disease 2019 Patients: Observational Cohort Study and Systematic Review. Open Forum Infect Dis 2020;7:ofaa199. [PMID: 32548209 DOI: 10.1093/ofid/ofaa199] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 21.0] [Reference Citation Analysis]
103 Guiot J, Henket M, Frix AN, Delvaux M, Denis A, Giltay L, Thys M, Gester F, Moutschen M, Corhay JL, Louis R; COVID-19 clinical investigators of the CHU de Liège. Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic. Respir Investig 2020:S2212-5345(20)30124-6. [PMID: 32978099 DOI: 10.1016/j.resinv.2020.08.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
104 Monti S, Montecucco C. Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: ‘Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)’ by Giollo et al. Ann Rheum Dis 2021;80:e13-e13. [DOI: 10.1136/annrheumdis-2020-217638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Tiendrébéogo WJS, Kaboré F, Diendéré EA, Ouedraogo DD. Case Series of Chronic Inflammatory Rheumatic Disease Patients Infected by Coronavirus Disease 2019 (COVID-19). Case Rep Rheumatol 2020;2020:8860492. [PMID: 33224548 DOI: 10.1155/2020/8860492] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Koc NS, Yildirim T, Saglam A, Arici M, Erdem Y. A patient with COVID-19 and anti-glomerular basement membrane disease. Nefrología (English Edition) 2021;41:471-3. [DOI: 10.1016/j.nefroe.2021.08.008] [Reference Citation Analysis]
107 Spelman T, Forsberg L, McKay K, Glaser A, Hillert J. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry. Mult Scler 2021;:13524585211026272. [PMID: 34212816 DOI: 10.1177/13524585211026272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Khurana A, Saxena S. Immunosuppressive agents for dermatological indications in the ongoing COVID-19 pandemic: Rationalizing use and clinical applicability. Dermatol Ther 2020;33:e13639. [PMID: 32436617 DOI: 10.1111/dth.13639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
109 Arleo T, Tong D, Shabto J, O'Keefe G, Khosroshahi A. Clinical course and outcomes of COVID-19 in rheumatic disease patients: a case cohort study with a diverse population. Clin Rheumatol 2021;40:2633-42. [PMID: 33420870 DOI: 10.1007/s10067-021-05578-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
110 Kataoka H, Kodama F, Tomita T, Kondo M, Nagasaka A, Nishikawa S, Mukai M. Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab. Intern Med 2021;60:639-43. [PMID: 33390490 DOI: 10.2169/internalmedicine.6010-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Conticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, Gentileschi S, Bennett D, Falsetti P, Lanzarone N, Bellisai F, Barreca C, D'Alessandro R, Cantarini L, Frediani B. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Ann Rheum Dis 2021;80:e14. [PMID: 32414804 DOI: 10.1136/annrheumdis-2020-217681] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
112 Robustillo-Villarino M, Álvarez-Arroyo L, Carrera-Hueso FJ, Barreda-Altaba I, Nieto-Cid M, Girona-Sanz AM, El-Qutob D. Characteristics of Patients With Immune-Mediated Inflammatory Diseases Hospitalized for SARS-CoV-2 Infection. Reumatol Clin (Engl Ed) 2021:S1699-258X(21)00088-7. [PMID: 33985907 DOI: 10.1016/j.reuma.2021.03.003] [Reference Citation Analysis]
113 Del Papa N, Sambataro G, Minniti A, Pignataro F, Caporali R. Novel COronaVirus Disease 2019 (COVID-19) epidemic: What are the risks for systemic sclerosis patients? Autoimmun Rev 2020;19:102558. [PMID: 32380317 DOI: 10.1016/j.autrev.2020.102558] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
114 Spihlman AP, Gadi N, Wu SC, Moulton VR. COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. Front Immunol 2020;11:589474. [PMID: 33193418 DOI: 10.3389/fimmu.2020.589474] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
115 Hakroush S, Franz J, Larsen J, Korsten P, Winkler MS, Tampe B. Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia. Ann Rheum Dis 2020:annrheumdis-2020-218491. [PMID: 32669300 DOI: 10.1136/annrheumdis-2020-218491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
116 Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. Telemedicine: a useful tool but not the holy grail. Response to: 'Telemedicine will not keep us apart in the COVID-19 pandemic' by Perniola et al. Ann Rheum Dis 2020:annrheumdis-2020-218071. [PMID: 32503856 DOI: 10.1136/annrheumdis-2020-218071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
117 Akama-Garren EH, Li JX. Prior immunosuppressive therapy is associated with mortality in COVID-19 patients: A retrospective study of 835 patients. J Med Virol 2021;93:5768-76. [PMID: 34042195 DOI: 10.1002/jmv.27105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Thanou A, Sawalha AH. SARS-CoV-2 and Systemic Lupus Erythematosus. Curr Rheumatol Rep 2021;23:8. [PMID: 33511495 DOI: 10.1007/s11926-020-00973-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
119 Elemam NM, Maghazachi AA, Hannawi S. COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. Curr Med Res Opin 2021;37:929-38. [PMID: 33754931 DOI: 10.1080/03007995.2021.1906637] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
120 Basheer M, Saad E, Laskar O, Schuster O, Rechnitzer H, Zisman-Rozen S, Azoulay D, Assy N. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery. Int J Mol Sci 2021;22:8902. [PMID: 34445605 DOI: 10.3390/ijms22168902] [Reference Citation Analysis]
121 Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, Catanoso M, Pipitone N, Cassone G, Girolimetto N, Croci S, Cimino L, Gradellini F, Beltrami M, Di Lernia V, Dolci G, Massari M, Marata AM, Costantini M, Giorgi Rossi P. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis 2020;79:986-8. [PMID: 32467245 DOI: 10.1136/annrheumdis-2020-217903] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
122 Louapre C, Maillart E, Roux T, Pourcher V, Bussone G, Lubetzki C, Papeix C. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum. Rev Neurol (Paris) 2020;176:523-5. [PMID: 32362357 DOI: 10.1016/j.neurol.2020.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
123 Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, Gomez-Reino J, Alvaro-Gracia JM; BIOBADASER study group. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis 2020;79:988-90. [PMID: 32503857 DOI: 10.1136/annrheumdis-2020-217948] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 19.0] [Reference Citation Analysis]
124 Lee JM, Lee SJ. Olfactory and Gustatory Dysfunction in a COVID-19 Patient with Ankylosing Spondylitis Treated with Etanercept: Case Report. J Korean Med Sci 2020;35:e201. [PMID: 32476306 DOI: 10.3346/jkms.2020.35.e201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
125 Joob B, Wiwanitkit V. Response to: 'Patients with lupus are not protected from COVID-19: a comment' by Sawalha, 'No evidence so far on the protective effect of hydroxycloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit' by Romão et al and 'SLE patients are not immune to COVID-19: importance of sending the right message across' by Goyal. Ann Rheum Dis 2021;80:e24. [PMID: 32404341 DOI: 10.1136/annrheumdis-2020-217695] [Reference Citation Analysis]
126 Blicharz L, Czuwara J, Samochocki Z, Goldust M, Chrostowska S, Olszewska M, Rudnicka L. Hand eczema-A growing dermatological concern during the COVID-19 pandemic and possible treatments. Dermatol Ther 2020;33:e13545. [PMID: 32384196 DOI: 10.1111/dth.13545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
127 Lwin M, Holroyd C, Wallis D, Davidson B, Goulston L, de Graaf H, Edwards CJ. Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs? Rheumatol Adv Pract 2020;4:rkaa061. [PMID: 33210076 DOI: 10.1093/rap/rkaa061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Xiao F, Han M, Zhu X, Tang Y, Huang E, Zou H, Jiang Q, Lu L. The immune dysregulations in COVID-19: Implications for the management of rheumatic diseases. Mod Rheumatol 2021;31:927-32. [PMID: 33427554 DOI: 10.1080/14397595.2020.1868673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Eviatar T, Elalouf O, Furer V, Goldstein-Lahat Y, Paran Y, Pel S, Nevo S, Zisapel M, Alcalay Y, Elkayam O. Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel. Intern Med J 2021;51:682-90. [PMID: 33844415 DOI: 10.1111/imj.15202] [Reference Citation Analysis]
130 Leszczyński P. COVID-19: a short message to rheumatologists. Reumatologia 2020;58:130-3. [PMID: 32684644 DOI: 10.5114/reum.2020.96685] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
131 Chang TS, Ding Y, Freund MK, Johnson R, Schwarz T, Yabu JM, Hazlett C, Chiang JN, Wulf A, Geschwind DH, Butte MJ, Pasaniuc B; UCLA Health Data Mart Working Group. Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System. medRxiv 2020:2020. [PMID: 32637977 DOI: 10.1101/2020.07.03.20145581] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 8.5] [Reference Citation Analysis]
132 Dettorre GM, Patel M, Gennari A, Pentheroudakis G, Romano E, Cortellini A, Pinato DJ. The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. ESMO Open 2021;6:100123. [PMID: 33932622 DOI: 10.1016/j.esmoop.2021.100123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
133 Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G, Urban ML, Vaglio A, Prisco D. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev. 2020;19:102575. [PMID: 32376395 DOI: 10.1016/j.autrev.2020.102575] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 42.5] [Reference Citation Analysis]
134 Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Marotte H, Servettaz A, Domont F, Chazerain P, Devaux M, Claudepierre P, Langlois V, Mekinian A, Maria ATJ, Banneville B, Fautrel B, Pouchot J, Thomas T, Flipo RM, Richez C; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors., FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 2021;3:e419-26. [PMID: 33786454 DOI: 10.1016/S2665-9913(21)00059-X] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 29.0] [Reference Citation Analysis]
135 Pope JE. What Does the COVID-19 Pandemic Mean for Rheumatology Patients? Curr Treatm Opt Rheumatol 2020;:1-4. [PMID: 32355607 DOI: 10.1007/s40674-020-00145-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
136 Mélo Silva Júnior ML, Souza LMA, Dutra REMC, Valente RGM, Melo TS. Review on therapeutic targets for COVID-19: insights from cytokine storm. Postgrad Med J 2021;97:391-8. [PMID: 33008960 DOI: 10.1136/postgradmedj-2020-138791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
137 Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G, Amor S. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 2020;202:149-61. [PMID: 32671831 DOI: 10.1111/cei.13495] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 37.5] [Reference Citation Analysis]
138 Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. 2020;Online ahead of print. [PMID: 32321723 DOI: 10.1136/annrheumdis-2020-217615] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 24.5] [Reference Citation Analysis]
139 Roux CH, Brocq O, Gerald F, Pradier C, Bailly L. Impact of Home Confinement During the COVID-19 Pandemic on Medication Use and Disease Activity in Spondyloarthritis Patients. Arthritis Rheumatol 2020;72:1771-2. [PMID: 32779880 DOI: 10.1002/art.41397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
140 Beyzaee AM, Rahmatpour Rokni G, Patil A, Goldust M. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review. Dermatol Ther. 2021;34:e14405. [PMID: 33051960 DOI: 10.1111/dth.14405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Batıbay S, Koçak Ulucaköy R, Özdemir B, Günendi Z, Göğüş FN. Clinical outcomes of Covid-19 in patients with rheumatic diseases and the effects of the pandemic on rheumatology outpatient care: A single-centre experience from Turkey. Int J Clin Pract 2021;75:e14442. [PMID: 34105856 DOI: 10.1111/ijcp.14442] [Reference Citation Analysis]
142 Álvarez Román MT, Butta Coll N, García Barcenilla S, Pérez González L, de la Plaza Collazo I, De la Corte Rodríguez H, Romero Garrido JA, Martín Salces M, Rivas Pollmar MI, Cebanu T, González-Zorrilla E, Acuña P, Monzón Manzano E, Rodríguez Merchán EC, Trelles Martínez R, Blanco Bañares MJ, Gutiérrez Alvariño M, Jiménez Yuste V. Registry of patients with congenital bleeding disorders and COVID-19 in Madrid. Haemophilia 2020;26:773-8. [PMID: 32524712 DOI: 10.1111/hae.14089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
143 Álvaro Gracia JM, Sanchez-Piedra C, Manero J, Ruiz-Lucea ME, López-Vives L, Bohorquez C, Martinez-Barrio J, Bonilla G, Vela P, García-Villanueva MJ, Navío-Marco MT, Pavía M, Galindo M, Erausquin C, Gonzalez-Gay MA, Rua-Figueroa I, Pego-Reigosa JM, Castrejon I, Sanchez-Costa JT, González-Dávila E, Diaz-Gonzalez F; COVIDSER study group. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. RMD Open 2021;7:e001925. [PMID: 34887346 DOI: 10.1136/rmdopen-2021-001925] [Reference Citation Analysis]
144 Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Tavoni A, Cecchetti R, Guiducci S, Ursini F, Caminiti M, Varcasia G, Gigliotti P, Pellegrini R, Olivo D, Colaci M, Murdaca G, Brittelli R, Mariano GP, Spinella A, Bellando-Randone S, Aiello V, Bilia S, Giannini D, Ferrari T, Caminiti R, Brusi V, Meliconi R, Fallahi P, Antonelli A; COVID-19 & ASD Italian Study Group. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol 2020;39:3195-204. [PMID: 32852623 DOI: 10.1007/s10067-020-05334-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
145 Coskun Benlidayi I, Kurtaran B, Tirasci E, Guzel R. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. Rheumatol Int 2020;40:1707-16. [PMID: 32591970 DOI: 10.1007/s00296-020-04635-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
146 Doná D, Torres Canizales J, Benetti E, Cananzi M, De Corti F, Calore E, Hierro L, Ramos Boluda E, Melgosa Hijosa M, Garcia Guereta L, Pérez Martínez A, Barrios M, Costa Reis P, Teixeira A, Lopes MF, Kaliciński P, Branchereau S, Boyer O, Debray D, Sciveres M, Wennberg L, Fischler B, Barany P, Baker A, Baumann U, Schwerk N, Nicastro E, Candusso M, Toporski J, Sokal E, Stephenne X, Lindemans C, Miglinas M, Rascon J, Jara P; ERN TransplantChild. Pediatric transplantation in Europe during the COVID-19 pandemic: Early impact on activity and healthcare. Clin Transplant 2020;34:e14063. [PMID: 32786120 DOI: 10.1111/ctr.14063] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
147 Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D, Alijotas-Reig J, Zinserling V, Semenova N, Amital H, Shoenfeld Y. Covid-19 and autoimmunity. Autoimmun Rev 2020;19:102597. [PMID: 32535093 DOI: 10.1016/j.autrev.2020.102597] [Cited by in Crossref: 123] [Cited by in F6Publishing: 119] [Article Influence: 61.5] [Reference Citation Analysis]
148 Kastritis E, Kitas GD, Vassilopoulos D, Giannopoulos G, Dimopoulos MA, Sfikakis PP. Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatol Int 2020;40:1353-60. [PMID: 32654078 DOI: 10.1007/s00296-020-04629-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
149 Melong Pianta Taleng CM, Lauper K, Gilbert B, Cunningham T, Guemara R, Brulhart L, Dan D, Courvoisier D, Finckh A. Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab. RMD Open 2021;7:e001711. [PMID: 34862310 DOI: 10.1136/rmdopen-2021-001711] [Reference Citation Analysis]
150 Monti S, Montecucco C. Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al. Ann Rheum Dis 2021;80:e68. [PMID: 32591359 DOI: 10.1136/annrheumdis-2020-218148] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Ayele AG, Enyew EF, Kifle ZD. Roles of existing drug and drug targets for COVID-19 management. Metabol Open 2021;11:100103. [PMID: 34222852 DOI: 10.1016/j.metop.2021.100103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Yeoh SA, Ehrenstein MR. Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic? Lancet Rheumatol 2020;2:e454-6. [PMID: 32835250 DOI: 10.1016/S2665-9913(20)30175-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
153 Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 2021;80:71-87. [PMID: 33158881 DOI: 10.1136/annrheumdis-2020-218398] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
154 Martín Navarro JA, Cintra Cabrera M, Lucca Proccacini F, Muñoz Rodríguez J, Roldán Cortés D, Lucena Valverde R, Ortega Díaz M, Puerta Carretero M, Gil Herrera J, Jaldo Rodríguez MT, Albalate Ramón M, Corchete Prats E, Medina Zahonero L, de Sequera Ortiz P, Alcázar Arroyo R. More difficult still: Treating severe rapidly progressive glomerulonephritis in the context of COVID-19 pneumonia. Nefrologia (Engl Ed) 2021:S0211-6995(21)00012-6. [PMID: 33781578 DOI: 10.1016/j.nefro.2020.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Koc NS, Yildirim T, Saglam A, Arici M, Erdem Y. A patient with COVID-19 and anti-glomerular basement membrane disease. Nefrologia 2021;41:471-3. [PMID: 33139077 DOI: 10.1016/j.nefro.2020.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
156 Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, Erra A, Serrat M, Espartal E, Antón S, Añez GA, Caparrós-Ruiz R, Pluma A, Trallero-Araguás E, Barceló-Bru M, Almirall M, De Agustín JJ, Lladós J, Julià A, Marsal S. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 2020;50:564-70. [PMID: 32425260 DOI: 10.1016/j.semarthrit.2020.05.001] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 34.0] [Reference Citation Analysis]
157 Monti S, Montecucco C. Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev et al. Ann Rheum Dis 2021;80:e17. [PMID: 32434818 DOI: 10.1136/annrheumdis-2020-217800] [Reference Citation Analysis]
158 Kordzadeh-Kermani E, Khalili H, Karimzadeh I. Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). Future Microbiol 2020;15:1287-305. [PMID: 32851877 DOI: 10.2217/fmb-2020-0110] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
159 Duret PM, Spielmann L, Messer L. Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina et al. Ann Rheum Dis 2021;80:e80. [PMID: 32816687 DOI: 10.1136/annrheumdis-2020-218147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 D'Silva KM, Wallace ZS. COVID-19 and Disease-Modifying Anti-rheumatic Drugs. Curr Rheumatol Rep 2021;23:28. [PMID: 33893890 DOI: 10.1007/s11926-021-00998-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
161 Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, Laffan M, Makris M, Newland AC, Provan D, Grainger JD, Hill QA. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol 2020;189:1038-43. [PMID: 32374026 DOI: 10.1111/bjh.16775] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 19.0] [Reference Citation Analysis]
162 D’silva KM, Serling-boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, Choi HK, Sparks JA, Wallace ZS. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’. Ann Rheum Dis 2020;79:1156-62. [DOI: 10.1136/annrheumdis-2020-217888] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 43.0] [Reference Citation Analysis]
163 Lommatzsch M, Rabe KF, Taube C, Joest M, Kreuter M, Wirtz H, Blum TG, Kolditz M, Geerdes-fenge H, Otto-knapp R, Häcker B, Schaberg T, Ringshausen FC, Vogelmeier CF, Reinmuth N, Reck M, Gottlieb J, Konstantinides S, Meyer J, Worth H, Windisch W, Welte T, Bauer T. Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. Respiration 2022;101:307-20. [DOI: 10.1159/000518896] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Amani L, Warraich R, Patel N, Tahir H. COVID-19 and rheumatology: is shielding really necessary? Br J Hosp Med 2020;81:1-3. [DOI: 10.12968/hmed.2020.0284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
165 Shih AR, Misdraji J. COVID-19: Gastrointestinal and Hepatobiliary Manifestations. Hum Pathol 2022:S0046-8177(22)00179-4. [PMID: 35843340 DOI: 10.1016/j.humpath.2022.07.006] [Reference Citation Analysis]
166 Ward D, Gørtz S, Ernst MT, Andersen NN, Kjær SK, Hallas J, Christensen S, Christiansen CF, Israelsen SB, Benfield T, Pottegård A, Jess T. The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. Eur Respir J 2021:2100769. [PMID: 34475227 DOI: 10.1183/13993003.00769-2021] [Reference Citation Analysis]
167 Beydon M, Chevalier K, Al Tabaa O, Hamroun S, Delettre AS, Thomas M, Herrou J, Riviere E, Mariette X. Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis. 2020;Online ahead of print. [PMID: 32327427 DOI: 10.1136/annrheumdis-2020-217573] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 21.0] [Reference Citation Analysis]
168 Costi S, Caporali R, Cimaz R. Dealing with COVID-19 in a Pediatric Rheumatology Unit in Italy. Paediatr Drugs 2020;22:263-4. [PMID: 32297225 DOI: 10.1007/s40272-020-00395-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
169 Murray K, Quinn S, Turk M, O'Rourke A, Molloy E, O'Neill L, Mongey AB, Fearon U, Veale DJ. COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population. Rheumatology (Oxford) 2021;60:902-6. [PMID: 33164088 DOI: 10.1093/rheumatology/keaa694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
170 Sinagra JL, Vedovelli C, Binazzi R, Salemme A, Moro F, Mazzanti C, Didona B, Di Zenzo G. Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab. Front Immunol 2021;12:665522. [PMID: 33936104 DOI: 10.3389/fimmu.2021.665522] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Ortolan A, Lorenzin M, Cosma C, Cozzi G, Padoan A, Doria A, Plebani M, Ramonda R. SARS-CoV-2 Infection in Spondyloarthritis Patients Treated With Biotechnological Drugs: A Study on Serology. Front Immunol 2021;12:682850. [PMID: 34177927 DOI: 10.3389/fimmu.2021.682850] [Reference Citation Analysis]
172 D'Silva KM, Wallace ZS. COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol 2021;33:255-61. [PMID: 33625043 DOI: 10.1097/BOR.0000000000000786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
173 Bose S, Adapa S, Aeddula NR, Roy S, Nandikanti D, Vupadhyayula PM, Naramala S, Gayam V, Muppidi V, Konala VM. Medical Management of COVID-19: Evidence and Experience. J Clin Med Res 2020;12:329-43. [PMID: 32587649 DOI: 10.14740/jocmr4201] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
174 Kjeldsen J, Nielsen J, Ellingsen T, Knudsen T, Nielsen RG, Larsen MD, Lund K, Nørgård BM. Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark. J Autoimmun 2021;120:102632. [PMID: 33812171 DOI: 10.1016/j.jaut.2021.102632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
175 Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, Castrejón I, Álvaro-Gracia J. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int 2020;40:1593-8. [PMID: 32794113 DOI: 10.1007/s00296-020-04676-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
176 Smolen JS. Greetings from the editor. Ann Rheum Dis 2020;79:677-8. [PMID: 32434810 DOI: 10.1136/annrheumdis-2020-217811] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
177 Ayala Gutiérrez MDM, Rubio-Rivas M, Romero Gómez C, Montero Sáez A, Pérez de Pedro I, Homs N, Ayuso García B, Cuenca Carvajal C, Arnalich Fernández F, Beato Pérez JL, Vargas Núñez JA, Letona Giménez L, Suárez Fernández C, Méndez Bailón M, Tuñón de Almeida C, González Moraleja J, de Guzmán García-Monge M, Helguera Amezua C, Fidalgo Montero MDP, Giner Galvañ V, Gil Sánchez R, Collado Sáenz J, Boixeda R, Ramos Rincón JM, Gómez Huelgas R, On Behalf Of The Semi-Covid-Network. Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry. J Clin Med 2021;10:1844. [PMID: 33922777 DOI: 10.3390/jcm10091844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Jethwa H, Sullivan A, Abraham S. COVID-19 and Immunomodulatory Therapy - Can We Use Data from Previous Viral Pandemics? J Rheumatol 2020;47:1734-7. [PMID: 32423974 DOI: 10.3899/jrheum.200527] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
179 Cai K, He J, Wong PK, Manolios N. The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia. Eur J Rheumatol 2020;7:S91-3. [PMID: 32352360 DOI: 10.5152/eurjrheum.2020.20060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
180 Choy E, Groves L, Sugrue D, Hurst M, Houghton J, Venkatachalam S, Patel YI, Maxwell JR, Pollock KG, Henning S. Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. BMC Rheumatol 2021;5:3. [PMID: 33536080 DOI: 10.1186/s41927-020-00173-0] [Reference Citation Analysis]
181 Xu C, Yi Z, Cai R, Chen R, Thong BY, Mu R. Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. Autoimmun Rev 2021;20:102778. [PMID: 33609804 DOI: 10.1016/j.autrev.2021.102778] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
182 Ziadé N, Hmamouchi I, El Kibbi L, Abdulateef N, Halabi H, Abutiban F, Hamdi W, El Rakawi M, Eissa M, Masri B. The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. Clin Rheumatol 2020;39:3205-13. [PMID: 32996071 DOI: 10.1007/s10067-020-05428-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
183 Lommatzsch M, Rabe KF, Taube C, Joest M, Kreuter M, Wirtz H, Blum TG, Kolditz M, Geerdes-Fenge H, Otto-Knapp R, Häcker B, Schaberg T, Ringshausen FC, Vogelmeier CF, Reinmuth N, Reck M, Gottlieb J, Konstantinides S, Meyer FJ, Worth H, Windisch W, Welte T, Bauer T. [Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]. Pneumologie 2021;75:19-30. [PMID: 33242887 DOI: 10.1055/a-1321-3400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
184 Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, Jung B, Larcher R, Klouche K, Le Moing V. Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac et al. Ann Rheum Dis 2020:annrheumdis-2020-217955. [PMID: 32503848 DOI: 10.1136/annrheumdis-2020-217955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
185 Furer V, Rondaan C, Agmon-Levin N, van Assen S, Bijl M, Kapetanovic MC, de Thurah A, Mueller-Ladner U, Paran D, Schreiber K, Warnatz K, Wulffraat NM, Elkayam O. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open 2021;7:e001594. [PMID: 33627440 DOI: 10.1136/rmdopen-2021-001594] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
186 Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, Antinori S, Galli M. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38:337-342. [PMID: 32202240 DOI: 10.1016/j.autrev.2020.102574] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
187 Loarce-Martos J, García-Fernández A, López-Gutiérrez F, García-García V, Calvo-Sanz L, Del Bosque-Granero I, Terán-Tinedo MA, Boteanu A, Bachiller-Corral J, Vázquez-Díaz M. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int 2020;40:2015-21. [PMID: 32945944 DOI: 10.1007/s00296-020-04699-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
188 Sharmeen S, Elghawy A, Zarlasht F, Yao Q. COVID-19 in rheumatic disease patients on immunosuppressive agents. Semin Arthritis Rheum 2020;50:680-6. [PMID: 32512263 DOI: 10.1016/j.semarthrit.2020.05.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
189 Rathi M, Singh P, Bi HP, Shivanna A, Kavadichanda C, Tripathy SR, Parthasarathy J, Tota S, Maurya S, Vijayalekshmi V, Bhavani D, Jain A, Gupta R, Danda D, Rajasekhar L, Negi VS, Shobha V, Das B, Aggarwal A. Impact of the COVID-19 pandemic on patients with systemic lupus erythematosus: Observations from an Indian inception cohort. Lupus 2021;30:158-64. [DOI: 10.1177/0961203320962855] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
190 Vasconcelos J, Portugal R, Torres R, Falcão S. Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab. BMJ Case Rep 2021;14:e243338. [PMID: 34183316 DOI: 10.1136/bcr-2021-243338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Chang TS, Ding Y, Freund MK, Johnson R, Schwarz T, Yabu JM, Hazlett C, Chiang JN, Wulf DA, Geschwind DH, Butte MJ, Pasaniuc B; UCLA Precision Health Data Discovery Repository Working Group. Pre-existing conditions in Hispanics/Latinxs that are COVID-19 risk factors. iScience 2021;24:102188. [PMID: 33615196 DOI: 10.1016/j.isci.2021.102188] [Reference Citation Analysis]
192 Ren YR, Golding A, Sorbello A, Ji P, Chen J, Saluja B, Witzmann K, Arya V, Reynolds KS, Choi SY, Nikolov NP, Sahajwalla C. A Comprehensive Updated Review on SARS-CoV-2 and COVID-19. J Clin Pharmacol 2020;60:954-75. [PMID: 32469437 DOI: 10.1002/jcph.1673] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
193 Monti S, Montecucco C. Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini et al. Ann Rheum Dis 2021;80:e15. [PMID: 32414805 DOI: 10.1136/annrheumdis-2020-217738] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
194 Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 mo of the pandemic. JHEP Rep. 2020;2:100169. [PMID: 32835190 DOI: 10.1016/j.jhepr.2020.100169] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 34.0] [Reference Citation Analysis]
195 Gupta L, Misra DP, Agarwal V, Balan S, Agarwal V. Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India. Ann Rheum Dis 2020;80:e1-e1. [DOI: 10.1136/annrheumdis-2020-217509] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
196 Benucci M, Damiani A, Giannasi G, Li Gobbi F, Quartuccio L, Grossi V, Infantino M, Manfredi M. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD. Ann Rheum Dis. [DOI: 10.1136/annrheumdis-2020-218214] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
197 Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, Jung B, Larcher R, Klouche K, Le Moing V. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis 2021;80:e10. [PMID: 32312768 DOI: 10.1136/annrheumdis-2020-217549] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 32.5] [Reference Citation Analysis]
198 Abbas AM, AbouBakr A. Rheumatoid Arthritis in the Era of COVID-19 Pandemic. Mediterr J Rheumatol 2020;31:257-8. [PMID: 33196002 DOI: 10.31138/mjr.31.3.257] [Reference Citation Analysis]
199 Raman R, Patel KJ, Ranjan K. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules 2021;11:993. [PMID: 34356617 DOI: 10.3390/biom11070993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Espinosa G, Araujo O, Amaro S, Bodro M, Moreno PJ, Moreno R, Ugarte A, Cervera R. COVID-19 and Behçet’s disease: clinical case series. Ann Rheum Dis 2021;80:e41-e41. [DOI: 10.1136/annrheumdis-2020-217778] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
201 Kifle ZD, Ayele AG, Enyew EF. Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. J Environ Public Health 2021;2021:6631721. [PMID: 33953756 DOI: 10.1155/2021/6631721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 So H, Mak JW, So J, Lui G, Lun F, Lee J, Chan S, Ho C, Chan JM, Kong SP, Ng WL, Tam LS. Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study. Semin Arthritis Rheum 2020;50:885-9. [PMID: 32896705 DOI: 10.1016/j.semarthrit.2020.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
203 Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y, Tu W, Chen Y, Yu Y, Wu X, Chen Y, Zhong J, Dong L. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis 2020;79:1007-13. [PMID: 32444415 DOI: 10.1136/annrheumdis-2020-217627] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 31.0] [Reference Citation Analysis]
204 Jovani V, Calabuig I, Peral-Garrido ML, Tovar-Sugrañes E, López-González MD, Bernabeu P, Martínez A, Esteve-Vives J, León-Ramírez JM, Moreno-Perez O, Boix V, Gil J, Merino E, Vela P, Andrés M. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. Ann Rheum Dis 2020:annrheumdis-2020-218152. [PMID: 32586922 DOI: 10.1136/annrheumdis-2020-218152] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
205 Clarke C, Lucisano G, Prendecki M, Gleeson S, Martin P, Ali M, McAdoo SP, Lightstone L, Ashby D, Charif R, Griffith M, McLean A, Dor F, Willicombe M; ICHNT Renal COVID Group. Informing the Risk of Kidney Transplantation Versus Remaining on the Waitlist in the Coronavirus Disease 2019 Era. Kidney Int Rep 2021;6:46-55. [PMID: 33173838 DOI: 10.1016/j.ekir.2020.10.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
206 Accorinti M, Manni P, Sampalmieri L, Saturno MC. Ocular Behçet disease and COVID-19. European Journal of Ophthalmology. [DOI: 10.1177/11206721221074437] [Reference Citation Analysis]
207 Jessica Chang TY, Pope JE. How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology. Immunotherapy 2020;12:1115-9. [PMID: 32640861 DOI: 10.2217/imt-2020-0153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
208 Tamartash Z, Javinani A, Gharibdoost F, Atef Yekta R, Mohammadzadegan A, Kavosi H. The clinical course of COVID-19 in systemic sclerosis patients, report from 150 patients. Intern Emerg Med 2021. [PMID: 33864203 DOI: 10.1007/s11739-021-02727-7] [Reference Citation Analysis]
209 Duron G, Gelman L, Dua A, Putman M. Tracking clinical resources for coronavirus disease 2019. Curr Opin Rheumatol 2020;32:441-8. [PMID: 32675716 DOI: 10.1097/BOR.0000000000000724] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
210 Allwood BW, Koegelenberg CF, Irusen E, Lalla U, Davids R, Chothia Y, Davids R, Prozesky H, Taljaard J, Parker A, Decloedt E, Jordan P, Lahri S, Moosa R, Schrueder N, Du Toit R, Viljoen A, English R, Ayele B, Nyasulu P; COVID-19 Research Response Team, Faculty of Medicine and Health Sciences, Stellenbosch University. Clinical evolution, management and outcomes of patients with COVID-19 admitted at Tygerberg Hospital, Cape Town, South Africa: a research protocol. BMJ Open 2020;10:e039455. [PMID: 32868368 DOI: 10.1136/bmjopen-2020-039455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
211 Batu ED, Lamot L, Sag E, Ozen S, Uziel Y. How the COVID-19 pandemic has influenced pediatric rheumatology practice: Results of a global, cross-sectional, online survey. Semin Arthritis Rheum 2020;50:1262-8. [PMID: 33065421 DOI: 10.1016/j.semarthrit.2020.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
212 Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 2021;80:e67. [PMID: 32591357 DOI: 10.1136/annrheumdis-2020-218075] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
213 Baba H, Kanamori H, Oshima K, Seike I, Niitsuma-Sugaya I, Takei K, Sato Y, Tokuda K, Aoyagi T. Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide. J Infect Chemother 2020;26:1100-3. [PMID: 32631736 DOI: 10.1016/j.jiac.2020.06.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
214 Leso V, Fontana L, Iavicoli I. Susceptibility to Coronavirus (COVID-19) in Occupational Settings: The Complex Interplay between Individual and Workplace Factors. Int J Environ Res Public Health 2021;18:1030. [PMID: 33503829 DOI: 10.3390/ijerph18031030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
215 Tang X, Geng L, Feng X, Sun L. Decreased serum ACE2 levels in patients with connective tissue diseases. Rheumatology 2021;60:4401-6. [DOI: 10.1093/rheumatology/keaa898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
216 Bonek K, Roszkowski L, Massalska M, Maslinski W, Ciechomska M. Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells 2021;10:323. [PMID: 33557301 DOI: 10.3390/cells10020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Agrawal R, Testi I, Lee CS, Tsui E, Blazes M, Thorne JE, Okada AA, Smith JR, McCluskey PJ, Kempen JH, Tappeiner C, Agarwal M, Bodaghi B, Nguyen QD, Gupta V, De Smet MD, Zierhut M, Pavesio C; COVID-19 IMT Study Group. Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic. Br J Ophthalmol 2021;105:639-47. [PMID: 32586933 DOI: 10.1136/bjophthalmol-2020-316776] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
218 Greco R, Alexander T, Burman J, Del Papa N, de Vries-Bouwstra J, Farge D, Henes J, Kazmi M, Kirgizov K, Muraro PA, Ricart E, Rovira M, Saccardi R, Sharrack B, Snarski E, Withers B, Jessop H, Boglione C, Kramer E, Badoglio M, Labopin M, Orchard K, Corbacioglu S, Ljungman P, Mikulska M, De la Camara R, Snowden JA; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP), Infectious Diseases Working Party (IDWP), Pediatric Working Party (PWP), Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE), EBMT Nurses Group and Patient Advocacy Committee. Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transplant 2021;56:1493-508. [PMID: 34031556 DOI: 10.1038/s41409-021-01326-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
219 Santos-Moreno P, Chavez-Chavez J, Hernández-Zambrano SM, Rivera-Triana DP, Castiblanco-Montañez RA, Aza A, Buitrago-Garcia D, Villarreal L, Rojas-Villarraga A. Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic. Ann Rheum Dis 2021;80:e65. [PMID: 32586920 DOI: 10.1136/annrheumdis-2020-218165] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
220 Martín Navarro JA, Cintra Cabrera M, Proccacini F, Muñoz Rodríguez J, Roldán Cortés D, Lucena Valverde R, Ortega Díaz M, Puerta Carretero M, Gil Herrera J, Jaldo Rodríguez MT, Albalate Ramón M, Corchete Prats E, Medina Zahonero L, de Sequera Ortiz P, Alcázar Arroyo R. More difficult still: Treating severe rapidly progressive glomerulonephritis in the context of COVID-19 pneumonia. Nefrología (English Edition) 2022. [DOI: 10.1016/j.nefroe.2020.12.007] [Reference Citation Analysis]
221 Razanamahery J, Soumagne T, Humbert S, Brunel AS, Lepiller Q, Daguindau E, Mansi L, Chirouze C, Bouiller K. Does type of immunosupression influence the course of Covid-19 infection? J Infect 2020;81:e132-5. [PMID: 32504741 DOI: 10.1016/j.jinf.2020.05.075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
222 Lahouati M, Mériglier E, Martin L, Bouchet S, Desclaux A, Bonnet F. COVID-19 infection also occurs in patients taking hydroxychloroquine. J Antimicrob Chemother 2020;75:2014-5. [PMID: 32417904 DOI: 10.1093/jac/dkaa193] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
223 Tehrani HA, Darnahal M, Vaezi M, Haghighi S. COVID-19 associated thrombotic thrombocytopenic purpura (TTP) ; A case series and mini-review. Int Immunopharmacol 2021;93:107397. [PMID: 33524803 DOI: 10.1016/j.intimp.2021.107397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
224 Strippoli D, Barbagallo T, Prestinari F, Russo G, Fantini F. Biologic agents in psoriasis: our experience during coronavirus infection. Int J Dermatol 2020;59:e266-7. [PMID: 32516447 DOI: 10.1111/ijd.15002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
225 Nas K, Eryilmaz N, Geyik MF, Altaş A. COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review. Rheumatol Int 2021;41:811-7. [PMID: 33611657 DOI: 10.1007/s00296-021-04809-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, Colomer JI, Jover JA, Fernandez-Gutierrez B, Abasolo L. Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Schulze-Koops et al. Ann Rheum Dis 2020:annrheumdis-2020-219230. [PMID: 33127661 DOI: 10.1136/annrheumdis-2020-219230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
227 Rodriguez-Pla A, Vikram HR, Khalid V, Wesselius LJ. COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review. Rheumatol Int 2021;41:1509-14. [PMID: 34091704 DOI: 10.1007/s00296-021-04905-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Haslak F, Ozbey D, Yildiz M, Adrovic A, Sahin S, Koker O, Aliyeva A, Guliyeva V, Yalcin G, Inanli G, Kocazeybek BS, Kasapcopur O, Barut K. Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children. Clin Rheumatol. [DOI: 10.1007/s10067-022-06067-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
229 Silva CA, Queiroz LB, Fonseca CB, Silva LEVD, Lourenço B, Marques HHS. Spotlight for healthy adolescents and adolescents with preexisting chronic diseases during the COVID-19 pandemic. Clinics (Sao Paulo) 2020;75:e1931. [PMID: 32401965 DOI: 10.6061/clinics/2020/e1931] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
230 Furlan A, Forner G, Cipriani L, Vian E, Rigoli R, Gherlinzoni F, Scotton P. COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge. Front Immunol 2021;12:763412. [PMID: 34804051 DOI: 10.3389/fimmu.2021.763412] [Reference Citation Analysis]
231 Piemonti L, Landoni G. COVID-19 and islet transplantation: Different twins. Am J Transplant 2020;20:2983-8. [PMID: 32400017 DOI: 10.1111/ajt.16001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
232 Aydın F, Kurt T, Sezer M, Tekgöz N, Ekici Tekin Z, Kanık Yüksek S, Çelikel Acar B. Biological therapies in children with rheumatic diseases during the COVID-19 pandemic: A single-centre experience. Int J Clin Pract 2021;75:e14030. [PMID: 34233400 DOI: 10.1111/ijcp.14030] [Reference Citation Analysis]
233 Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, Cozzi G, Depascale R, Zanatta E, Gasparotto M, Benvenuti F, Bindoli S, Gatto M, Felicetti M, Ortolan A, Campaniello D, Larosa M, Lorenzin M, Ramonda R, Sfriso P, Schiavon F, Iaccarino L, Doria A. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. J Autoimmun 2020;112:102502. [PMID: 32527675 DOI: 10.1016/j.jaut.2020.102502] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 21.5] [Reference Citation Analysis]
234 Cosset JM, Deutsch É, Bazire L, Mazeron JJ, Chargari C. [Low dose lung radiotherapy for COVID-19-related cytokine storm syndrome: Why not?]. Cancer Radiother 2020;24:179-81. [PMID: 32389579 DOI: 10.1016/j.canrad.2020.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
235 Schulze-Koops H, Skapenko A, Krause A, Krueger K, Lorenz HM, Sewerin P, Specker C, Wagner UG, Voormann A, Mueller-Ladner U, Voll RE. Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'. Ann Rheum Dis 2020:annrheumdis-2020-218997. [PMID: 33127664 DOI: 10.1136/annrheumdis-2020-218997] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
236 Tariq S, Van Eeden C, Tervaert JWC, Osman MS. COVID-19, rheumatic diseases and immune dysregulation-a perspective. Clin Rheumatol 2021;40:433-42. [PMID: 33411143 DOI: 10.1007/s10067-020-05529-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
237 Mena Vázquez N, Manrique-Arija S, Cabezudo-García P, Godoy-Navarrete FJ, Cabezas-Lucena AM, Morales-Águila M, Redondo-Rodríguez R, Sobrino B, Ureña-Garnica I, Ordoñez-Cañizares MC, Díaz Cordovés-Rego G, Fernández-Nebro A. Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases. Int J Clin Pract 2021;75:e13707. [PMID: 32931643 DOI: 10.1111/ijcp.13707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
238 Romão VC, Cruz-Machado AR, Fonseca JE. No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit. Ann Rheum Dis 2021;80:e22. [PMID: 32404340 DOI: 10.1136/annrheumdis-2020-217665] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
239 Capecchi PL, Lazzerini PE, Volterrani L, Mazzei MA, Rossetti B, Zanelli G, Bennett D, Bargagli E, Franchi F, Cameli M, Valente S, Cantarini L, Frediani B. Antirheumatic agents in covid-19: is IL-6 the right target? Ann Rheum Dis 2021;80:e2. [PMID: 32299796 DOI: 10.1136/annrheumdis-2020-217523] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
240 Leipe J, Wilke EL, Ebert MP, Teufel A, Reindl W. Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab. Semin Arthritis Rheum 2020;50:1087-8. [PMID: 32916559 DOI: 10.1016/j.semarthrit.2020.06.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
241 Avouac J, Airó P, Carlier N, Matucci-cerinic M, Allanore Y. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. Ann Rheum Dis 2021;80:e37-e37. [DOI: 10.1136/annrheumdis-2020-217864] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 16.0] [Reference Citation Analysis]
242 Batu ED, Özen S. Implications of COVID-19 in pediatric rheumatology. Rheumatol Int 2020;40:1193-213. [PMID: 32500409 DOI: 10.1007/s00296-020-04612-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
243 Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R, Montecucco C. Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data? Arthritis Rheumatol 2020;72:1600-6. [PMID: 32506699 DOI: 10.1002/art.41388] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 27.0] [Reference Citation Analysis]
244 Janda A, Schuetz C, Canna S, Gorelik M, Heeg M, Minden K, Hinze C, Schulz A, Debatin KM, Hedrich CM, Speth F. Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists. Rheumatol Int 2021;41:911-20. [PMID: 33683393 DOI: 10.1007/s00296-021-04824-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
245 Movahedi N, Ziaee V. COVID-19 and myositis; true dermatomyositis or prolonged post viral myositis? Pediatr Rheumatol Online J 2021;19:86. [PMID: 34112199 DOI: 10.1186/s12969-021-00570-w] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
246 Cavagna L, Seminari E, Zanframundo G, Gregorini M, Di Matteo A, Rampino T, Montecucco C, Pelenghi S, Cattadori B, Pattonieri EF, Vitulo P, Bertani A, Sambataro G, Vancheri C, Biglia A, Bozzalla-Cassione E, Bonetto V, Monti MC, Ticozzelli E, Turco A, Oggionni T, Corsico A, Bertuccio F, Zuccaro V, Codullo V, Morosini M, Marena C, Gnecchi M, Pellegrini C, Meloni F. Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy. Microorganisms 2020;8:E977. [PMID: 32629788 DOI: 10.3390/microorganisms8070977] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
247 Talarico R, Stagnaro C, Ferro F, Carli L, Mosca M. Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection. Lancet Rheumatol 2020;2:e518-9. [PMID: 32838313 DOI: 10.1016/S2665-9913(20)30216-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
248 Tavares ACFMG, de Melo AKG, Cruz VA, de Souza VA, de Carvalho JS, Machado KLLL, de Azevedo Valadares LD, Dos Reis Neto ET, de Rezende RPV, de Resende Guimarães MFB, Ferreira GA, de Sousa Braz A, de Abreu Vieira RMR, de Medeiros Pinheiro M, Ribeiro SLE, Bica BEGR, Baptista KL, da Costa IP, Marques CDL, Lopes MLL, Martinez JE, Giorgi RDN, da Mota LMH, da Rocha Loures MAA, Dos Santos Paiva E, Monticielo OA, Xavier RM, Kakehasi AM, Pileggi GCS. Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force. Adv Rheumatol 2022;62:3. [PMID: 35039077 DOI: 10.1186/s42358-022-00234-7] [Reference Citation Analysis]
249 Giuliani F, Gualdi G, Amerio P. Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic. Dermatol Ther 2020;33:e14204. [PMID: 32829511 DOI: 10.1111/dth.14204] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
250 Haslak F, Gunalp A, Cebi MN, Yildiz M, Adrovic A, Sahin S, Barut K, Kasapcopur O. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study. Int J Rheum Dis 2022. [PMID: 34978376 DOI: 10.1111/1756-185X.14279] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
251 Miossec P. Synergy Between Cytokines and Risk Factors in the Cytokine Storm of COVID-19: Does Ongoing Use of Cytokine Inhibitors Have a Protective Effect? Arthritis Rheumatol 2020;72:1963-6. [PMID: 32725790 DOI: 10.1002/art.41458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
252 Kushner T, Cafardi J. Chronic Liver Disease and COVID-19: Alcohol Use Disorder/Alcohol-Associated Liver Disease, Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Autoimmune Liver Disease, and Compensated Cirrhosis. Clin Liver Dis (Hoboken). 2020;15:195-199. [PMID: 32537135 DOI: 10.1002/cld.974] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
253 Pakhchanian H, Khan H, Raiker R, Ahmed S, Kavadichanda C, Abbasi M, Kardeş S, Agarwal V, Aggarwal R, Gupta L. COVID-19 outcomes in patients with Dermatomyositis: a registry-based cohort analysis. Seminars in Arthritis and Rheumatism 2022. [DOI: 10.1016/j.semarthrit.2022.152034] [Reference Citation Analysis]
254 Tayebi Khosroshahi H, Mardomi A, Niknafs B, Farnood F, Shekarchi M, Salehi S, Fadaei Haggi T. Current status of COVID-19 among hemodialysis patients in the East Azerbaijan Province of Iran. Hemodial Int 2021;25:214-9. [PMID: 33275317 DOI: 10.1111/hdi.12907] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
255 Bae S, Ghang B, Kim YJ, Lim JS, Yun SC, Kim YG, Lee SO, Kim SH. Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea. Viruses 2021;13:329. [PMID: 33672785 DOI: 10.3390/v13020329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Perricone C, Gerli R. Being a rheumatologist and a patient with a rheumatic disease today: A perspective at the time of COVID-19. Eur J Rheumatol 2020;7:S89-90. [PMID: 32352358 DOI: 10.5152/eurjrheum.2020.2057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
257 Shimizu Y. Understanding the immunopathogenesis of COVID-19: Its implication for therapeutic strategy. World J Clin Cases 2020; 8(23): 5835-5843 [PMID: 33344582 DOI: 10.12998/wjcc.v8.i23.5835] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
258 Koker O, Demirkan FG, Kayaalp G, Cakmak F, Tanatar A, Karadag SG, Sonmez HE, Omeroglu R, Aktay Ayaz N. Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19. Rheumatol Int 2020;40:1613-23. [PMID: 32743705 DOI: 10.1007/s00296-020-04663-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
259 Tam LS, Tanaka Y, Handa R, Chang CC, Cheng YK, Isalm N, Li M, Lorenzo JP, Song YW, Yamamoto K, Zeng X, Haq SA. Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. Int J Rheum Dis 2020;23:717-22. [PMID: 32462761 DOI: 10.1111/1756-185X.13863] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
260 Kant S, Morris A, Ravi S, Floyd L, Gapud E, Antichos B, Dhaygude A, Seo P, Geetha D. The impact of COVID-19 pandemic on patients with ANCA associated vasculitis. J Nephrol 2021;34:185-90. [PMID: 33034038 DOI: 10.1007/s40620-020-00881-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
261 Alfishawy M, Nso N, Nassar M, Ariyaratnam J, Bhuiyan S, Siddiqui RS, Li M, Chung H, Al Balakosy A, Alqassieh A, Fülöp T, Rizzo V, Daoud A, Soliman KM. Liver transplantation during global COVID-19 pandemic. World J Clin Cases 2021; 9(23): 6608-6623 [PMID: 34447809 DOI: 10.12998/wjcc.v9.i23.6608] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
262 Massalska MA, Gober HJ. How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility. Front Immunol 2021;12:646894. [PMID: 34177895 DOI: 10.3389/fimmu.2021.646894] [Reference Citation Analysis]
263 Gabr H, Bastawy S, Abdel_aal AA, Khalil NM, Fateen M. Changes in peripheral blood cellular morphology as diagnostic markers for COVID‐19 infection. Int J Lab Hematology. [DOI: 10.1111/ijlh.13799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
264 Favalli EG, Gobbini A, Bombaci M, Maioli G, Biggioggero M, Pesce E, Favalli A, Martinovic M, Fabbris T, Marchisio E, Bandiera A, Gori A, Abrignani S, Grifantini R, Caporali R. The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study. Front Med 2022;9:850858. [DOI: 10.3389/fmed.2022.850858] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Schulze-Koops H, Krüger K, Hoyer BF, Leipe J, Iking-Konert C, Specker C; Commission for Pharmacotherapy and the Board of Directors of the German Society for Rheumatology. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2-methodology, key messages and justifying information. Rheumatology (Oxford) 2021;60:2128-33. [PMID: 33502500 DOI: 10.1093/rheumatology/keab072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
266 Quartuccio L, Valent F, Pasut E, Tascini C, De Vita S. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine 2020;87:439-43. [PMID: 32445935 DOI: 10.1016/j.jbspin.2020.05.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 22.0] [Reference Citation Analysis]
267 Pileggi GS, Ferreira GA, Reis APMG, Reis-Neto ET, Abreu MM, Albuquerque CP, Araújo NC, Bacchiega AB, Bianchi DV, Bica B, Bonfa ED, Borba EF, Brito DCSE, Duarte ÂLBP, Santo RCE, Fernandes PR, Guimarães MP, Gomes KWP, Kakehasi AM, Klumb EM, Lanna CCD, Marques CDL, Monticielo OA, Mota LMH, Munhoz GA, Paiva ES, Pereira HLA, Provenza JR, Ribeiro SLE, Junior LFR, Sampaio CSJC, Sampaio VS, Sato EI, Skare T, de Souza VA, Valim V, Lacerda MVG, Xavier RM, Pinheiro MM. Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. Adv Rheumatol 2021;61:60. [PMID: 34620246 DOI: 10.1186/s42358-021-00217-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Guarnotta V, Ferrigno R, Martino M, Barbot M, Isidori AM, Scaroni C, Ferrante A, Arnaldi G, Pivonello R, Giordano C. Glucocorticoid excess and COVID-19 disease. Rev Endocr Metab Disord 2020. [PMID: 33025384 DOI: 10.1007/s11154-020-09598-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
269 So H, Mok CC. COVID-19 and Rheumatic Diseases: Practical Issues. Journal of Clinical Rheumatology and Immunology 2020;20:21-4. [DOI: 10.1142/s2661341720300025] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
270 Fitzgerald KC, Mecoli CA, Douglas M, Harris S, Aravidis B, Albayda J, Sotirchos ES, Hoke A, Orbai AM, Petri M, Christopher-Stine L, Baer AN, Paik JJ, Adler BL, Tiniakou E, Timlin H, Bhargava P, Newsome SD, Venkatesan A, Chaudhry V, Lloyd TE, Pardo CA, Stern BJ, Lazarev M, Truta B, Saidha S, Chen ES, Sharp M, Gilotra N, Kasper EK, Gelber AC, Bingham CO 3rd, Shah AA, Mowry EM. RISK FACTORS FOR INFECTION AND HEALTH IMPACTS OF THE COVID-19 PANDEMIC IN PEOPLE WITH AUTOIMMUNE DISEASES. medRxiv 2021:2021. [PMID: 33564774 DOI: 10.1101/2021.02.03.21251069] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
271 Fitzgerald KC, Mecoli CA, Douglas M, Harris S, Aravidis B, Albayda J, Sotirchos ES, Hoke A, Orbai AM, Petri M, Christopher-Stine L, Baer AN, Paik JJ, Adler BL, Tiniakou E, Timlin H, Bhargava P, Newsome SD, Venkatesan A, Chaudhry V, Lloyd TE, Pardo CA, Stern BJ, Lazarev M, Truta B, Saidha S, Chen ES, Sharp M, Gilotra N, Kasper EK, Gelber AC, Bingham CO, Shah AA, Mowry EM. Risk Factors For Infection And Health Impacts Of The Covid-19 Pandemic In People With Autoimmune Diseases. Clin Infect Dis 2021:ciab407. [PMID: 33956972 DOI: 10.1093/cid/ciab407] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
272 Haslak F, Yildiz M, Adrovic A, Sahin S, Koker O, Aliyeva A, Barut K, Kasapcopur O. Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic. Rheumatol Int 2020;40:1423-31. [PMID: 32661928 DOI: 10.1007/s00296-020-04645-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
273 Mokuda S, Tokunaga T, Masumoto J, Sugiyama E. Angiotensin-converting Enzyme 2, a SARS-CoV-2 Receptor, Is Upregulated by Interleukin 6 through STAT3 Signaling in Synovial Tissues. J Rheumatol 2020;47:1593-5. [PMID: 32611670 DOI: 10.3899/jrheum.200547] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
274 Gracia BDC, Sáez L, Pallarés L, Velilla J, Marín A, Martinez-lostao L, Simeón CP, Fanlo P. COVID GEAS: COVID-19 National Survey in Patients With Systemic Autoimmune Diseases. Front Med 2022;8:808608. [DOI: 10.3389/fmed.2021.808608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
275 Guo Y, Hu K, Li Y, Lu C, Ling K, Cai C, Wang W, Ye D. Targeting TNF-α for COVID-19: Recent Advanced and Controversies. Front Public Health 2022;10:833967. [DOI: 10.3389/fpubh.2022.833967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
276 Felten R, Scherlinger M, Guffroy A, Poindron V, Meyer A, Giannini M, Korganow AS, Sordet C, Chatelus E, Javier RM, Meyer A, Pijnenburg L, Kleinmann JF, Gottenberg JE, Sibilia J, Martin T, Arnaud L. Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France. Arthritis Res Ther 2021;23:188. [PMID: 34256812 DOI: 10.1186/s13075-021-02565-0] [Reference Citation Analysis]
277 Temgoua MN, Endomba FT, Nkeck JR, Kenfack GU, Tochie JN, Essouma M. Coronavirus Disease 2019 (COVID-19) as a Multi-Systemic Disease and its Impact in Low- and Middle-Income Countries (LMICs). SN Compr Clin Med 2020;:1-11. [PMID: 32838173 DOI: 10.1007/s42399-020-00417-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
278 Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss MM, Heppt F, Meder C, Atreya R, Klenske E, Dietrich P, Abdullah A, Kliem T, Corte G, Morf H, Leppkes M, Kremer AE, Ramming A, Pachowsky M, Schuch F, Ronneberger M, Kleinert S, Maier C, Hueber AJ, Manger K, Manger B, Berking C, Tenbusch M, Überla K, Sticherling M, Neurath MF, Schett G. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun 2020;11:3774. [PMID: 32709909 DOI: 10.1038/s41467-020-17703-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 17.0] [Reference Citation Analysis]
279 Lakota K, Perdan-Pirkmajer K, Hočevar A, Sodin-Semrl S, Rotar Ž, Čučnik S, Žigon P. COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases. Front Immunol 2020;11:611318. [PMID: 33574819 DOI: 10.3389/fimmu.2020.611318] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
280 Cajamarca-Baron J, Guavita-Navarro D, Buitrago-Bohorquez J, Gallego-Cardona L, Navas A, Cubides H, Arredondo AM, Escobar A, Rojas-Villarraga A. [SARS-CoV-2 (COVID-19) in Patients with some Degree of Immunosuppression]. Reumatol Clin 2021;17:408-19. [PMID: 34630575 DOI: 10.1016/j.reuma.2020.08.004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
281 Vakil-Gilani K, O'Rourke K. Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19? Clin Rheumatol 2020;39:2067-8. [PMID: 32474884 DOI: 10.1007/s10067-020-05184-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Rossi G, Galosi L, Gavazza A, Cerquetella M, Mangiaterra S. Therapeutic approaches to coronavirus infection according to "One Health" concept. Res Vet Sci 2021;136:81-8. [PMID: 33588098 DOI: 10.1016/j.rvsc.2021.02.009] [Reference Citation Analysis]
283 Suárez-Díaz S, Morán-Castaño C, Coto-Hernández R, Mozo-Avellaneda L, Suárez-Cuervo C, Caminal-Montero L. Mild COVID-19 in ANCA-associated vasculitis treated with rituximab. Ann Rheum Dis 2020:annrheumdis-2020-218246. [PMID: 32769153 DOI: 10.1136/annrheumdis-2020-218246] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
284 Salem Hareedy M, Rashad SM, Hetta HF, Hassanien SM, Abdellatif H, Hassanien M. CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine. Drug Metab Pers Ther 2021. [PMID: 33770833 DOI: 10.1515/dmdi-2020-0164] [Reference Citation Analysis]
285 Jakhmola S, Indari O, Kashyap D, Varshney N, Rani A, Sonkar C, Baral B, Chatterjee S, Das A, Kumar R, Jha HC. Recent updates on COVID-19: A holistic review. Heliyon 2020;6:e05706. [PMID: 33324769 DOI: 10.1016/j.heliyon.2020.e05706] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
286 Ma MH, Tay SH, Cheung PP, Santosa A, Chan YH, Yip JW, Mak A, Lahiri M. Attitudes and Behaviors of Patients With Rheumatic Diseases During the Early Stages of the COVID-19 Outbreak. J Rheumatol 2021;48:35-9. [DOI: 10.3899/jrheum.200646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
287 Salesi M, Shojaie B, Naderi Z. Unexpected Positive Effects of Rituximab and Corticosteroids on COVID-19 in a Patient Suffering from Granulomatosis with Polyangiitis. Adv Biomed Res 2021;10:25. [PMID: 34760807 DOI: 10.4103/abr.abr_266_20] [Reference Citation Analysis]
288 Shoaib MH, Ahmed FR, Sikandar M, Yousuf RI, Saleem MT. A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. Front Pharmacol 2021;12:576448. [PMID: 33732150 DOI: 10.3389/fphar.2021.576448] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Shadmanfar S, Jonaidi-Jafari N, Jafari R, Rastgar-Moqaddam Z, Saburi A. COVID-19 in rheumatoid arthritis cases: an Iranian referral center experience. Clin Rheumatol 2021;40:2979-84. [PMID: 33219453 DOI: 10.1007/s10067-020-05464-y] [Reference Citation Analysis]
290 Ferri C, Giuggioli D, Raimondo V, Fallahi P, Antonelli A; COVID-19 & ASD Italian Study Group. COVID-19 in Italian patients with rheumatic autoimmune systemic diseases. Ann Rheum Dis 2020:annrheumdis-2020-219113. [PMID: 33055077 DOI: 10.1136/annrheumdis-2020-219113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
291 Günther C, Aschoff R, Beissert S. Cutaneous autoimmune diseases during COVID-19 pandemic. J Eur Acad Dermatol Venereol 2020;34:e667-70. [PMID: 32534461 DOI: 10.1111/jdv.16753] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
292 Solé G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P, Adams D, Laforet P, Tiffreau V, Desguerre I, Pisella LI, Molon A, Attarian S; FILNEMUS COVID-19 study group. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris) 2020;176:507-15. [PMID: 32354651 DOI: 10.1016/j.neurol.2020.04.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 16.5] [Reference Citation Analysis]
293 Vaid N, Ardissino M, Reed TAN, Goodall J, Utting P, Miscampbell M, Condurache D, Cohen DL. Clinical characteristics and outcomes of immunosuppressed patients hospitalized with COVID-19: experience from London. J Intern Med 2021;289:385-94. [PMID: 32902028 DOI: 10.1111/joim.13172] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
294 Giollo A, Adami G, Gatti D, Idolazzi L, Rossini M. Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID). Ann Rheum Dis 2021;80:e12-e12. [DOI: 10.1136/annrheumdis-2020-217598] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
295 Grange L, Guilpain P, Truchetet ME, Cracowski JL; French Society of Pharmacology and Therapeutics. Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review. Therapie 2020;75:335-42. [PMID: 32665090 DOI: 10.1016/j.therap.2020.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
296 Manansala M, Ascoli C, Alburquerque AG, Perkins D, Mirsaedi M, Finn P, Sweiss NJ. Case Series: COVID-19 in African American Patients With Sarcoidosis. Front Med (Lausanne) 2020;7:588527. [PMID: 33251236 DOI: 10.3389/fmed.2020.588527] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
297 Saxena S, Khurana A, B S, Sardana K, Agarwal A, Muddebihal A, Raina A, Paliwal P. Severe type 2 leprosy reaction with COVID-19 with a favourable outcome despite continued use of corticosteroids and methotrexate and a hypothesis on the possible immunological consequences. Int J Infect Dis 2021;103:549-51. [PMID: 33326870 DOI: 10.1016/j.ijid.2020.12.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
298 Miossec P. Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation. Eur J Rheumatol 2020;7:S97-8. [PMID: 32412405 DOI: 10.5152/eurjrheum.2020.2062] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
299 Brito CA, Paiva JG, Pimentel FN, Guimarães RS, Moreira MR. COVID-19 in patients with rheumatological diseases treated with anti-TNF. Ann Rheum Dis 2021;80:e62. [PMID: 32546603 DOI: 10.1136/annrheumdis-2020-218171] [Cited by in F6Publishing: 14] [Reference Citation Analysis]